4th Jun 2014 08:32
4 June 2014
Silence Therapeutics plc
Notice of General Meeting and posting of Annual Report
Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leading international RNA therapeutics company, will be holding its annual General Meeting on Friday, 27 June 2014 at 2pm at Silence Therapeutics, 1 Lyric Square, London, W6 0NB.
The Annual Report has today been posted to shareholders and can also be viewed online at: http://silence-therapeutics.com/investor-relations/reports-and-disclosures/.
Enquiries:
Silence Therapeutics plc | +44 (0)20 3700 9711 |
Tim Freeborn, Finance Director & Company Secretary | |
Rozi Morris, Communications Manager | |
Canaccord Genuity Limited | +44 (0)20 7523 8350 |
Lucy Tilley/Dr Julian Feneley/Henry Fitzgerald-O'Connor |
About Silence Therapeutics plc (www.silence-therapeutics.com)
Silence Therapeutics is a leading RNAi (RNA interference) therapeutics platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.
Listed on London's AIM since 2006, Silence is one of only six quoted companies globally with well-validated RNA delivery technology. It has a robust IP estate, with three Phase II trials already completed (pending results).
Related Shares:
SLN.L